Prime Medicine
Richard Brudnick is the current Chief Business Officer and Head of Strategy at Codiak BioSciences, a position they have held since June 2018. Prior to joining Codiak, Richard was a Partner at Israel Biotech Fund, and before that, they served as CBO at VolitionRx.
Richard has over 15 years of experience in the biotech and pharmaceutical industries, with a focus on business development, strategy, and finance. Richard has played a key role in the development and commercialization of several groundbreaking new treatments, including exosome therapeutics.
Under Richard's leadership, Codiak has become a world leader in exosome research and development, with a proprietary platform that can engineer exosomes to have precise and intentionally chosen properties. This cutting-edge technology is being used to develop novel treatments for a wide range of diseases, with the potential to transform the lives of millions of patients worldwide.
Richard Brudnick has a SM from the MIT Sloan School of Management and an SB from the Massachusetts Institute of Technology, both in Management Science.
Their manager is Keith Gottesdiener, President & CEO. Some of their coworkers include Carman Alenson - CAO & SVP, Finance, Jeremy Duffield - CSO, and Ann Lee - CTO.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.